JP6412500B2 - 免疫原性組成物 - Google Patents

免疫原性組成物 Download PDF

Info

Publication number
JP6412500B2
JP6412500B2 JP2015537218A JP2015537218A JP6412500B2 JP 6412500 B2 JP6412500 B2 JP 6412500B2 JP 2015537218 A JP2015537218 A JP 2015537218A JP 2015537218 A JP2015537218 A JP 2015537218A JP 6412500 B2 JP6412500 B2 JP 6412500B2
Authority
JP
Japan
Prior art keywords
protein
conjugated
serotype
saccharide
immunogenic composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2015537218A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015534962A (ja
Inventor
ヴェルラント，ヴィンセント
Original Assignee
グラクソスミスクライン バイオロジカルズ ソシエテ アノニム
グラクソスミスクライン バイオロジカルズ ソシエテ アノニム
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1218660.7A external-priority patent/GB201218660D0/en
Priority claimed from US13/826,932 external-priority patent/US20140193451A1/en
Priority claimed from US13/827,203 external-priority patent/US20140105927A1/en
Application filed by グラクソスミスクライン バイオロジカルズ ソシエテ アノニム, グラクソスミスクライン バイオロジカルズ ソシエテ アノニム filed Critical グラクソスミスクライン バイオロジカルズ ソシエテ アノニム
Publication of JP2015534962A publication Critical patent/JP2015534962A/ja
Application granted granted Critical
Publication of JP6412500B2 publication Critical patent/JP6412500B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/05—Actinobacteria, e.g. Actinomyces, Streptomyces, Nocardia, Bifidobacterium, Gardnerella, Corynebacterium; Propionibacterium
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/099—Bordetella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/102—Pasteurellales, e.g. Actinobacillus, Pasteurella; Haemophilus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55544—Bacterial toxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • C07K14/3156—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci from Streptococcus pneumoniae (Pneumococcus)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32611—Poliovirus
    • C12N2770/32634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • AIDS & HIV (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
JP2015537218A 2012-10-17 2013-10-15 免疫原性組成物 Expired - Fee Related JP6412500B2 (ja)

Applications Claiming Priority (13)

Application Number Priority Date Filing Date Title
US201261714942P 2012-10-17 2012-10-17
US201261714956P 2012-10-17 2012-10-17
US61/714,942 2012-10-17
GB1218660.7 2012-10-17
GBGB1218660.7A GB201218660D0 (en) 2012-10-17 2012-10-17 Immunogenic composition
US61/714,956 2012-10-17
US13/826,696 US9561268B2 (en) 2012-10-17 2013-03-14 Immunogenic composition
US13/827,203 2013-03-14
US13/826,696 2013-03-14
US13/826,932 US20140193451A1 (en) 2012-10-17 2013-03-14 Immunogenic composition
US13/826,932 2013-03-14
US13/827,203 US20140105927A1 (en) 2012-10-17 2013-03-14 Immunogenic composition
PCT/EP2013/071477 WO2014060385A1 (en) 2012-10-17 2013-10-15 Immunogenic composition

Publications (2)

Publication Number Publication Date
JP2015534962A JP2015534962A (ja) 2015-12-07
JP6412500B2 true JP6412500B2 (ja) 2018-10-24

Family

ID=53008966

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2015537218A Expired - Fee Related JP6412500B2 (ja) 2012-10-17 2013-10-15 免疫原性組成物
JP2015537220A Pending JP2015534964A (ja) 2012-10-17 2013-10-15 免疫原性組成物
JP2015537216A Active JP6236086B2 (ja) 2012-10-17 2013-10-15 １種以上の肺炎球菌莢膜糖類コンジュゲートとインフルエンザ菌由来のタンパク質Ｅおよび／またはＰｉｌＡを含むタンパク質成分とを含む免疫原性組成物

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2015537220A Pending JP2015534964A (ja) 2012-10-17 2013-10-15 免疫原性組成物
JP2015537216A Active JP6236086B2 (ja) 2012-10-17 2013-10-15 １種以上の肺炎球菌莢膜糖類コンジュゲートとインフルエンザ菌由来のタンパク質Ｅおよび／またはＰｉｌＡを含むタンパク質成分とを含む免疫原性組成物

Country Status (13)

Country Link
EP (3) EP2908856B1 (enExample)
JP (3) JP6412500B2 (enExample)
KR (2) KR20150072444A (enExample)
CN (2) CN104968366B (enExample)
AU (2) AU2013331781A1 (enExample)
BR (3) BR112015008417A8 (enExample)
CA (3) CA2888321A1 (enExample)
EA (2) EA201590490A1 (enExample)
ES (1) ES2640320T3 (enExample)
IL (2) IL238053A0 (enExample)
MX (2) MX365842B (enExample)
SG (2) SG11201502635SA (enExample)
WO (3) WO2014060383A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201218660D0 (en) 2012-10-17 2012-11-28 Glaxosmithkline Biolog Sa Immunogenic composition
US11160855B2 (en) 2014-01-21 2021-11-02 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
CN104306965B (zh) * 2014-10-31 2017-05-10 康希诺生物股份公司 预防肺炎链球菌感染性疾病的免疫原性组合物及制备方法
IL303998A (en) * 2015-07-21 2023-08-01 Pfizer Immunogenic preparations containing conjugated capsular sugar antigens, kits containing them and their uses
GB201518684D0 (en) * 2015-10-21 2015-12-02 Glaxosmithkline Biolog Sa Vaccine
GB201603029D0 (en) * 2016-02-22 2016-04-06 Glaxosmithkline Biolog Sa Vaccine
CN106432512B (zh) * 2016-09-30 2022-03-01 康希诺生物股份公司 一种增强多糖抗原免疫原性蛋白载体及其制备方法与应用
JP7446227B2 (ja) * 2018-01-19 2024-03-08 オービーアイ ファーマ，インコーポレイテッド Ｃｒｍ１９７タンパク質の発現方法
CN110540597B (zh) * 2018-12-20 2021-04-30 湖北工业大学 基于流感嗜血杆菌表面蛋白的乳胶微球免疫层析试纸的制备方法
MX2022013456A (es) * 2020-05-01 2022-11-16 Sinocelltech Ltd Metodo para mejorar la inmunogenicidad de un antigeno proteinico/peptidico.
KR20220142219A (ko) * 2021-04-14 2022-10-21 한국생명공학연구원 장내 미생물에서 단백질 분비를 유도하는 신호서열
EP4169513A1 (en) 2021-10-19 2023-04-26 GlaxoSmithKline Biologicals S.A. Adjuvant composition comprising sting agonists
CN117512031B (zh) * 2023-10-16 2024-06-25 江苏金迪克生物技术股份有限公司 一种肺炎球菌荚膜多糖的纯化方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000056359A2 (en) * 1999-03-19 2000-09-28 Smithkline Beecham Biologicals S.A. Vaccine against streptococcus pneumoniae
GB0108364D0 (en) * 2001-04-03 2001-05-23 Glaxosmithkline Biolog Sa Vaccine composition
SI1296715T2 (sl) * 2000-06-29 2016-03-31 Smithkline Beecham Biologicals S.A. Multivalentni sestavek cepiva
GB0022742D0 (en) * 2000-09-15 2000-11-01 Smithkline Beecham Biolog Vaccine
GB0130215D0 (en) * 2001-12-18 2002-02-06 Glaxosmithkline Biolog Sa Vaccine
SI2192127T1 (sl) * 2003-12-23 2012-10-30 Nationwide Children S Hospital Inc Pili tipa IV iz Haemophilus influenzae
EP2298794A3 (en) * 2005-07-08 2011-04-06 Nationwide Children's Hospital, Inc. Chimeric vaccine for haemophilus influenzae-induced disease
CA2636566C (en) * 2006-01-17 2018-03-13 Arne Forsgren A novel surface exposed haemophilus influenzae protein (protein e; pe)
KR101579947B1 (ko) * 2007-06-26 2015-12-28 글락소스미스클라인 바이오로지칼즈 에스.에이. 스트렙토코쿠스 뉴모니애 캡슐 다당류 컨쥬게이트를 포함하는 백신
CA2748149C (en) * 2008-12-24 2018-03-06 Netherlands Vaccine Institute Modified steptococcus pneumonia pneumolysin (ply) polypeptides
KR101512053B1 (ko) * 2009-09-03 2015-04-28 화이자 백신스 엘엘씨 Ｐｃｓｋ９ 백신
JP5894083B2 (ja) * 2009-12-22 2016-03-23 サノフィ パストゥール リミテッドＳａｎｏｆｉ Ｐａｓｔｅｕｒ Ｌｉｍｉｔｅｄ 免疫原性組成物
JP6046632B2 (ja) * 2010-12-03 2016-12-21 サノフィ パストゥール リミテッドＳａｎｏｆｉ Ｐａｓｔｅｕｒ Ｌｉｍｉｔｅｄ 肺炎球菌に対する免疫用組成物
JP5944480B2 (ja) * 2011-03-22 2016-07-05 セルム・インスティテュート・オブ・インディア・ピーブイティー．・リミテッド 多糖を調製するための新規な方法
TW201302779A (zh) * 2011-04-13 2013-01-16 Glaxosmithkline Biolog Sa 融合蛋白質及組合疫苗
AU2012257771C1 (en) * 2011-05-17 2015-12-03 Glaxosmithkline Biologicals S.A. Vaccine against Streptococcus pneumoniae

Also Published As

Publication number Publication date
CA2888300A1 (en) 2014-04-24
CN104853768A (zh) 2015-08-19
JP2015534964A (ja) 2015-12-07
CA2888310C (en) 2021-07-06
CA2888321A1 (en) 2014-04-24
IL238079A0 (en) 2015-05-31
WO2014060389A2 (en) 2014-04-24
EP2908856A1 (en) 2015-08-26
MX2015004949A (es) 2015-07-06
BR112015008418A2 (pt) 2017-07-04
WO2014060389A3 (en) 2014-09-12
CN104968366A (zh) 2015-10-07
WO2014060383A1 (en) 2014-04-24
BR112015008419A8 (pt) 2019-09-10
AU2013331781A1 (en) 2015-05-07
JP2015536312A (ja) 2015-12-21
EP2908854A2 (en) 2015-08-26
SG11201502634TA (en) 2015-05-28
BR112015008419A2 (pt) 2017-07-04
AU2013331781A8 (en) 2015-05-14
AU2013333975A1 (en) 2015-05-07
WO2014060385A1 (en) 2014-04-24
BR112015008417A8 (pt) 2019-09-10
BR112015008419B1 (pt) 2022-11-08
JP2015534962A (ja) 2015-12-07
EP2908855B1 (en) 2017-06-28
EA201590490A1 (ru) 2015-10-30
EA201590491A1 (ru) 2016-01-29
BR112015008417A2 (pt) 2017-07-04
CA2888310A1 (en) 2014-04-24
KR20150072444A (ko) 2015-06-29
IL238053A0 (en) 2015-05-31
JP6236086B2 (ja) 2017-11-22
ES2640320T3 (es) 2017-11-02
CN104853768B (zh) 2019-04-19
MX365842B (es) 2019-06-17
MX2015005002A (es) 2015-07-17
EP2908856B1 (en) 2019-02-20
CN104968366B (zh) 2017-12-01
EP2908855A1 (en) 2015-08-26
KR20150058571A (ko) 2015-05-28
SG11201502635SA (en) 2015-05-28

Similar Documents

Publication Publication Date Title
JP6412500B2 (ja) 免疫原性組成物
AU2018225099B2 (en) Enhancing immunogenicity of Streptococcus pneumoniae polysaccharide-protein conjugates
JP5848790B2 (ja) 肺炎連鎖球菌莢膜多糖コンジュゲートを含むワクチン
AU2010348155B2 (en) Immunogenic composition comprising S. pneumoniae polysaccharides conjugated to carrier proteins
CN103585623B (zh) 含有肺炎链球菌荚膜多糖缀合物的疫苗
US11844828B2 (en) Vaccine
US20050214329A1 (en) Vaccine
CZ305324B6 (cs) Imunogenní prostředek, způsob jeho přípravy, vakcína s jeho obsahem a léčivo obsahující pneumokokový polysacharidový antigen v kombinaci s proteinovým antigenem Streptococcus pneumoniae
CZ20013379A3 (cs) Vakcína
KR20220016964A (ko) 에스. 뉴모니아에 혈청형 29에 대해 보호하는 면역원성 조성물을 사용하여 환자를 치료하는 방법
JP2020128372A (ja) 髄膜炎菌組成物およびその方法
US20150079132A1 (en) Evoking protection against streptotoccus pneumoniae incorporating b-cell and t-cell pneumococcal protein antigens and pneumococcal polysaccharides delivered concomitantly
US20140193451A1 (en) Immunogenic composition
US20140105927A1 (en) Immunogenic composition

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150617

A529 Written submission of copy of amendment under article 34 pct

Free format text: JAPANESE INTERMEDIATE CODE: A529

Effective date: 20150608

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20160913

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170801

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20171101

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20180403

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180803

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20180810

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20180911

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20180928

R150 Certificate of patent or registration of utility model

Ref document number: 6412500

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees